Product manufacturing and product phenotype. (A) Manufacturing schema of PLAT-02–formulated CD19 CAR products. (B) Flow cytometric phenotype of input apheresis T cells and final products (FPs). (C) Frequency of transgene-expressing T cells in formulated CD4 and CD8 products based on EGFRt flow cytometric enumeration. (D) EGFRt transgene expression levels of formulated products based on mean fluorescence intensity (MFI). PBMC, peripheral blood mononuclear cell; SP, starting products.